Serological Response to COVID-19 and Its Association With Measles-Rubella (MR)-Containing Vaccines

• Published in: Curēus (Palo Alto, CA) Vol. 15; no. 5; p. e39671
• Main Authors: Shrivastava, Jahnavi, Narang, Manish, Ahmed, Rafat S, Das, Shukla, Gomber, Sunil
• Format: Journal Article
• Language: English
• Published: United States Springer Nature B.V 29.05.2023; Cureus
• Subjects: Allergy/Immunology; Antibodies; Antigens; Asymptomatic; COVID-19 vaccines; Diabetes; Disease; Immune response; Infections; Infectious Disease; Measles; Pathogens; Pediatrics; Rubella; Serology; Severe acute respiratory syndrome coronavirus 2; Statistical analysis; India; antibody response; rubella vaccine; children; immune response; measles vaccine; vaccine efficacy; immunogenicity; sars-cov-2
• DOI: 10.7759/cureus.39671
• ISSN: 2168-8184

 Epidemiological studies suggest that coronavirus disease 2019 (COVID-19) has a less severe disease course and a more favorable prognosis among children. Childhood vaccines and heterologous immunity have been suggested as reasons for this. Additionally, the structural similarity between the measles, rubella, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus particles may affect immune responses. The objective of this study was to compare COVID-19 antibody titers and disease severity between measles-rubella (MR) vaccinated and unvaccinated children. Additionally, we aimed to evaluate and compare the antibody response in recipients of a single dose and two doses of the MR vaccine.  The study was prospective and comparative and included 90 COVID-19-positive children aged nine months to 12 years. The study was registered under the clinical trials registry of India (CTRI/2021/01/030363). COVID-19 antibody titers were measured at two weeks, six weeks, and 12 weeks, along with the assessment of MR antibody titers. COVID-19 antibody titers and disease severity were compared between MR-vaccinated and MR-unvaccinated children. The comparison of COVID-19 antibody titers between recipients of a single dose and two doses of MR vaccine was also conducted. The results showed significantly higher median COVID-19 antibody titers at all time points during follow-up in the MR-vaccinated group (P<0.05). However, the two groups had no significant difference in the disease severity. Moreover, there was no difference in the antibody titers of MR one dose and two dose recipients. Exposure to even a single dose of MR-containing vaccine enhances the antibody response against COVID-19. However, randomized trials are necessary to further explore this subject.